H.C. Wainwright reiterates a Buy rating on MannKind (MNKD) with a $9 price target saying it views the scPharmaceuticals (SCPH) acquisition positively. MannKind shares will benefit from a more diversified revenue base and the company paid a “very reasonable” price to acquire scPharmaceuticals, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- H.C. Wainwrights positive on MannKind deal for scPharmaceuticals
- Keurig Dr Pepper buys JDE Peet’s, Thoma Bravo to acquire Verint: Morning Buzz
- MannKind’s Strategic Acquisition of scPharmaceuticals: A Catalyst for Future Growth and Value Creation
- MannKind’s Strategic Acquisition and Growth Prospects: A Buy Rating by Yun Zhong
- MannKind Announces Acquisition of scPharmaceuticals